Pattern of care of high-grade gliomas;Prise en charge des gliomes de haut grade

Revue du Praticien

Volumn 56, Issue 16, 2006, Pages 1779-1786

  Laigle Donadey, Florence ^b   Sanson, Marc ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CARBOPLATIN; CARMUSTINE; CORTICOSTEROID; ETOPOSIDE; FOTEMUSTINE; GADOLINIUM; HEPARIN; LOMUSTINE; PREDNISOLONE; TEMOZOLOMIDE;

ARTICLE; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; OLIGODENDROGLIOMA; PATIENT CARE; QUALITY OF LIFE; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR GROWTH;

ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; EPILEPSY; FORECASTING; GENETIC MARKERS; GLIOBLASTOMA; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROGNOSIS; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; THROMBOEMBOLISM; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33751008401     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323-31.
2. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360-4.
3. Cairncross JG, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013-21.
4. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
5. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-93.
6. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer 1997;33:1592-6.
7. Stupp R, van den Bent MJ, Weller M, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
8. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008-12.
9. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol 2003;5:79-88.
10. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
11. Stupp R, Hegi ME, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 2006;11:165-80.
12. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-22.
13. Sanson M, Aguirre-Cruz L, Cartalat-Carel S, Hoanq-Xuan K. Oligodendrogliomas: an update on basic and clinical research. Curr Neurol Neurosci Rep 2003;3:223-8.
14. Idbaih A MY, Pierron G, Brennetot C, et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 2005;58:483-7.
15. Hegi ME, Diserens AC, Gorlia T, Hamou MF, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
16. Keime-Guibert F, Chinot O, Taillandier L, et al. Phase 3 study comparing radiotherapy with supportive care in older patients with newly diagnosed anaplastic astrocytomas or glioblastoma multiforme: an ANOCEF group trial. 6th meeting of the European Association of Neurooncology 5-8 Mai 2005, Edimbourg. Neurooncol 2005;3:349 (abstract 260).
17. Chinot O. Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 2001;28:13-8.
18. Chinot OL, Barrie M, Frauger E, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004;100:2208-14.
19. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.